Royalty Pharma PLC at Citi BioPharma Conference Transcript
I would like to introduce our next session from Royalty Pharma. We have an old friend from Citi, my former counterpart, Chris Hite. And I have an old friend from my Morgan Stanley days, Marshall Urist, so Vice Chairman, and separately, Head of R&D. So thank you both. I don't know whether you want to give a few words in terms of update.
I mean, you're busy prosecuting your business, expanding the capital you have, allocating it, the common refrain that we get when we speak to investors. And frankly, it's not as often as it should be because it doesn't get the attention that it warrants, is great company, lousy stock. So anyway, I thought that was an interesting way to start the conversation. So Chris, over to you and just maybe give us an update.
Well, thank you for having us, and good to see you. I kind of -- I think I like our stock. We had a very successful Analyst Day in May,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |